Collaboration Renal MRI Creating room and momentum through - - PowerPoint PPT Presentation

▶

Sep 30, 2022 475 likes •617 views

Collaboration Renal MRI Creating room and momentum through facilitation Registered charity no. 252892. Scottish charity no. SC039245. Patient survey on research priorities Weighted Score for research priorities 0 1000 2000 3000 4000

SLIDE 1

Registered charity no. 252892. Scottish charity no. SC039245.

Collaboration Renal MRI “Creating room and momentum through facilitation”

SLIDE 2

Registered charity no. 252892. Scottish charity no. SC039245.

1000 2000 3000 4000 5000 6000 7000 8000 Cures for kidney disease Prevention of kidney disease Finding new sources of organ transplants Early detection of kidney diseases Improving treatments to make damaged kidneys last longer Improving methods of transplantation Stem cell research

Weighted Score for research priorities

2,200 responses All stages of disease pathway represented Third survey undertaken by the charity

Patient survey on research priorities

SLIDE 3

Registered charity no. 252892. Scottish charity no. SC039245.

UK Renal Research Strategy

Launched 14th April 2016

Balanced UKRRS Steering Group Patients Collaboration

SLIDE 4

Registered charity no. 252892. Scottish charity no. SC039245.

SLIDE 5

Registered charity no. 252892. Scottish charity no. SC039245.

Measuring the return from pharmaceutical innovation – 2016 (7th Annual Report)

Blockbuster costs; average cost to bring an asset from discovery to market : > $1.5 billion Regulatory hurdles Operational environment challenges

Some Partnership Challenges…

Innovation ? Making a difference ? Hope?

SLIDE 6

Registered charity no. 252892. Scottish charity no. SC039245.

New Collaborative Opportunities

SLIDE 7

Registered charity no. 252892. Scottish charity no. SC039245.

SLIDE 8

SLIDE 9

The lack of predictive biomarkers of disease progression is currently the largest single obstacle for the development of treatments for CKD”

Target engagement Biomarkers Disease Progression Biomarkers

Disease progression Biomarker = Something that will tell us whether CKD is in a stable (ie. losing <2ml/min/yr GFR, progressive (2-5 ml/min/yr) or rapidly progressive (> 5ml/min/yr GFR) state in a spot sample

Value Appreciation:

SLIDE 10

UK Regenerative Medicine Network UK Renal Imaging Network UK Fibrosis - Network

SLIDE 11

Iron and Muscle

Assessing the impact of IV iron therapy on exercise & physical capacity in CKD patients

SLIDE 12

Registered charity no. 252892. Scottish charity no. SC039245.

Creative Imagination

SLIDE 13

Registered charity no. 252892. Scottish charity no. SC039245.

Facilitation - bridging
Governance
Communications to support

publication activity

PPI
Share learnings and best practice

Equitable – open and objective partnerships Sustainability Impact